Leeward Investments LLC MA Sells 3,017 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Leeward Investments LLC MA lowered its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 384,191 shares of the life sciences company’s stock after selling 3,017 shares during the period. Leeward Investments LLC MA owned approximately 0.49% of Integra LifeSciences worth $16,732,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Swiss National Bank increased its position in shares of Integra LifeSciences by 0.9% during the third quarter. Swiss National Bank now owns 161,994 shares of the life sciences company’s stock valued at $6,187,000 after acquiring an additional 1,500 shares in the last quarter. Cooke & Bieler LP lifted its stake in shares of Integra LifeSciences by 4.4% during the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after buying an additional 120,410 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of Integra LifeSciences during the 3rd quarter valued at $43,034,000. Cardinal Capital Management lifted its stake in shares of Integra LifeSciences by 1.6% during the 4th quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after buying an additional 347 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Integra LifeSciences during the 3rd quarter valued at $25,443,000. Institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on IART shares. Truist Financial lowered their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research note on Friday, March 1st. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research note on Wednesday, April 3rd. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Finally, JMP Securities decreased their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $28.34 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of 34.14, a PEG ratio of 0.86 and a beta of 1.12. The firm’s 50-day moving average is $35.34 and its 200 day moving average is $38.76. Integra LifeSciences Holdings Co. has a 12 month low of $27.18 and a 12 month high of $56.21.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. During the same period in the previous year, the company posted $0.94 EPS. Integra LifeSciences’s revenue for the quarter was down .3% on a year-over-year basis. Research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.